==== Front Int J Med Sci Int J Med Sci ijms International Journal of Medical Sciences 1449-1907 Ivyspring International Publisher Sydney 10.7150/ijms.47193 ijmsv18p0120 Research Paper Risk factors related to the severity of COVID-19 in Wuhan Zhao Chen 1 Bai Yan 1✉ Wang Cencen 1 Zhong Yanyan 2 Lu Na 1 Tian Li 1 Cai Fucheng 1 Jin Runming 1 1 Department of Pediatric, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan, 430022, P.R. China. 2 Huazhong University of Science and Technology Hostipal. Luoyu Road 1037, Wuhan, 430074, P.R China. ✉ Corresponding author: Yan Bai, Department of Pediatric, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan, 430022, P.R. China. Tel.: +86 18872283653; E-mail: yanbaixh@hust.edu.cn. Competing Interests: The authors have declared that no competing interest exists. 2021 1 1 2021 18 1 120127 21 4 2020 13 10 2020 © The author(s) 2021 This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Objective: To evaluate the characteristics at admission of patients with moderate COVID-19 in Wuhan and to explore risk factors associated with the severe prognosis of the disease for prognostic prediction. Methods: In this retrospective study, moderate and severe disease was defined according to the report of the WHO-China Joint Mission on COVID-19. Clinical characteristics and laboratory findings of 172 patients with laboratory-confirmed moderate COVID-19 were collected when they were admitted to the Cancer Center of Wuhan Union Hospital between February 13, 2020 and February 25, 2020. This cohort was followed to March 14, 2020. The outcomes, being discharged as mild cases or developing into severe cases, were categorized into two groups. The data were compared and analyzed with univariate logistic regression to identify the features that differed significantly between the two groups. Based on machine learning algorithms, a further feature selection procedure was performed to identify the features that can contribute the most to the prediction of disease severity. Results: Of the 172 patients, 112 were discharged as mild cases, and 60 developed into severe cases. Four clinical characteristics and 18 laboratory findings showed significant differences between the two groups in the statistical test (P<0.01) and univariate logistic regression analysis (P<0.01). In the further feature selection procedure, six features were chosen to obtain the best performance in discriminating the two groups with a linear kernel support vector machine. The mean accuracy was 91.38%, with a sensitivity of 0.90 and a specificity of 0.94. The six features included interleukin-6, high-sensitivity cardiac troponin I, procalcitonin, high-sensitivity C-reactive protein, chest distress and calcium level. Conclusions: With the data collected at admission, the combination of one clinical characteristic and five laboratory findings contributed the most to the discrimination between the two groups with a linear kernel support vector machine classifier. These factors may be risk factors that can be used to perform a prognostic prediction regarding the severity of the disease for patients with moderate COVID-19 in the early stage of the disease. COVID-19 moderate cases severe prognosis risk factors severity prognostic prediction machine learning ==== Body Introduction COVID-19 was initially reported in Wuhan, China, in December 2019 and rapidly spread to all other provinces in China and throughout the world 1, 2. Without specific treatment or prevention options for COVID-19, such as targeted antiviral drugs and vaccines, China has focused on isolation, quarantine, social distancing, and community containment to contain the outbreak 3. By May 18, 2020, there were 84,494 confirmed cases of COVID-19 and 4,645 deaths in China and 4,534,327 confirmed cases and 307,202 deaths outside of China 4. The pandemic of COVID-19 has raised wide public concern and imposed a heavy burden on global health care systems because approximately 15-20% of patients develop severe interstitial pneumonia 5. In addition, COVID-19 patients admitted to ICUs experienced higher mortality (38%) than non-ICU patients (4%) 6. A mortality rate of 50-60% was reported in patients developing ARDS and requiring invasive mechanical ventilation therapy in the ICU 7. Patients with COVID-19 were divided into mild, moderate, severe, and critical cases 8. Because of the high mortality rate in severe or critical patients 6, 7, early identification of patients' risk of developing into severe or critical cases is important so that patients with a poor prognosis can receive timely intervention and minimize the progression of the disease 9. Therefore, prognostic tools and biomarkers are urgently needed 10, 11. However, most studies have focused mainly on identifying the factors related to death and recovery 12-14. Although some prognostic information has been revealed by using univariate- or multivariate analyses based on prior clinical knowledge or evidence 9, 15-21, these studies have not paid enough attention to feature selection in multivariate prognostic prediction modeling. As a result, the published prognostic prediction tools may not make the most of patient data to perform prognostic prediction modeling. This study built a multivariate prognostic prediction model to predict the risk of developing severe cases among patients with moderate COVID-19. With the patients' characteristics at admission and outcomes, a feature selection procedure based on machine learning algorithms was conducted to identify the features contributing the most to distinguishing between the two groups. These features were then chosen as the risk factors on which to build the prognostic prediction model. We believe that this multivariate prognostic prediction tool will be of considerable value for patients with moderate COVID-19 in isolation or self-quarantine so that they can receive timely intervention and active intensive care to minimize progression of the disease and so that health care agencies can prioritize their services, especially in resource-constrained areas. Materials and methods The ethics committees of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology approved this retrospective study. The requirement for informed consent was waived. This study was conducted in accordance with the Declaration of Helsinki. Patients In this retrospective, single-center study, a search for patient data in the electronic record system was performed for patients admitted to the Cancer Center of Wuhan Union Hospital between February 13, 2020 and February 25, 2020. According to the report of the WHO-China Joint Mission on COVID-19, patients with COVID-19 were divided into mild (laboratory confirmed, without pneumonia), moderate (laboratory confirmed and with pneumonia), severe (dyspnea, respiratory frequency ≥30 beats per minute (bpm), oxygen saturation (SpO2) ≤93%, PaO2/FiO2 ratio <300, and/or lung infiltrates >50% of the lung field within 24-48 hours), and critical (respiratory failure requiring mechanical ventilation, shock, or other organ failure that requires intensive care) cases 8. Our institution was a designated hospital capable of receiving patients with moderate, severe and critical cases of COVID-19. The inclusion criteria in this study were as follows: (1) patients with laboratory-confirmed COVID-19 according to viral nucleic acid detection using RT-PCR with samples from pharynx swabs; (2) patients who underwent complete laboratory tests (routine blood tests, biochemistry analysis, cytokine tests, immunology tests, and L subset tests) and clinical recording at admission; and (3) patients diagnosed with moderate COVID-19 at admission. The flow diagram of the exclusion criteria is shown in Figure 1. Treatments The number of patients with COVID-19 is rapidly growing worldwide, and specialized treatment has not been available in the early stage of the global outbreak. Patients in this study were moderate cases, and their treatments followed the therapeutic principles based on the 2019-nCoV guidelines (Trial Version 5) proposed by the China National Health Commission 22. The basic treatment included antiviral treatment (abidor 200 mg three times daily, orally), antibacterial treatment (moxifloxacin 400 mg once daily, orally), recombinant human interferon α2b (aerosol inhalation) and symptomatic treatment. Some of the moderate cases were treated with traditional Chinese medicine. However, they were not included in this study, as shown in Figure 1. Data collection This cohort was followed to March 14, 2020. Patient data were obtained at admission, including demographics, comorbidities, signs and symptoms, and laboratory findings. The assessed comorbidities included hypertension, cardiovascular disease, diabetes, malignancy, cerebrovascular disease, COPD, chronic kidney disease, chronic liver disease, HIV infection, rheumatic disease and hyperuricemia. The laboratory findings were obtained through the complete laboratory tests mentioned earlier. Finally, 172 patients with moderate COVID-19 at admission were included in this study. In addition, 112 cases were discharged as mild cases, whereas 60 cases developed into severe or critical cases. Statistical analysis and prognostic prediction modeling Descriptive statistics were used to describe the demographics, comorbidities, signs and symptoms, and laboratory findings of the 172 moderate cases. Between the two groups, categorical data were compared by using the chi-squared test (Fisher's exact test if the expected count was fewer than 5 for at least one cell). Continuous variables were compared using the independent variable t-test (Mann-Whitney U test if the data were not normally distributed). Univariate logistic regression models were also built to identify the potential risk factors related to the severe prognosis of COVID-19. As a result, the features that differed significantly between the two groups in the above statistics test (P<0.01) and were significant in univariate logistic regression (P<0.01) were chosen as candidates for further processing as follows. First, multivariate logistic regression analysis with L1 regularization was performed with feature standardization. The regression aimed to identify a subset of features from the aforementioned candidate features that could contribute the most to the discrimination between the two groups 23. In addition, a parameter sweep on the C parameter was performed in the mentioned L1 regularization. Second, an SVM classifier with a linear kernel was adopted to measure the prediction performance of the top k features from the aforementioned subset. The top k features were selected according to their coefficients in the previous multivariate logistic regression (k ranged from 1 to the size of the subset). Finally, the top k features with the highest 5-fold SVM classification accuracy were chosen as the most predictive features to perform the clinical prognostic prediction modeling with a linear kernel SVM model. The predicted probability (pi) of a moderate case developing into a severe one was calculated with the following equation: ln [pi/(1-pi)] = a0 + a1 * xi1 +…+ ak * xik. For the ith individual, xik was the kth indicator variable in the prognostic prediction model, and aik was the weight for the kth feature. a0 is the intercept. The statistical analysis was performed using SPSS 22 (SPSS, Inc., Chicago, IL, USA). SVM modeling and multivariate logistic regression modeling with L1 regularization used Python (Version 3.7) and the scikit-learn package (Version 0.22.1) 24. Results Clinical characteristics The basic information about the two groups is summarized in Table 1. The median age of the patients was 65 years (IQR 57-71 years). Patients in the severe group were significantly older than those in the mild group (P<0.001), with an average age of 70.6 (SD 11.6) and a median age of 64 (IRQ 50-67), respectively. Among the 172 cases, 52.3% of the patients were female. There was a higher female proportion in the mild group than in the severe group (P=0.01). Comorbidities were present in 55.2% of the patients, but the difference between the two groups was not significant. Hypertension and diabetes were the most common comorbidities. For each kind of comorbidity, there was no significant difference between the two groups. As shown in Table 2, 15 signs or symptoms were recorded in these moderate cases at admission. Fever, dry cough, and fatigue were the most common initial symptoms (63.4%, 55.2%, and 58.1%, respectively). But fever and dry cough showed no significant difference between the two groups, while fatigue was significantly different. Chest distress and anorexia were significantly more common in the severe group than in the mild group (P<0.001). In the univariate logistic regression analysis, age, chest distress, fatigue, and anorexia showed significant differences regarding to the outcomes (P<0.01), as shown in Table 4. Laboratory findings Laboratory findings on hospital admission are summarized in Table 3. Among the 172 patients, 19 laboratory findings showed significant differences between the two groups. Patients in the severe group demonstrated significantly increased WBC, N count, N percentage, AST, LDH, TNI, CK, CK-MB, CysC, ESR, CRP, PCT, IL-6, and IL-10 but significantly decreased L count, L percentage, A/G, ALB, and Ca (P<0.01). In the univariate logistic regression analysis, these laboratory findings also showed significant differences regarding to the outcomes (P<0.01), except CK-MB, as shown in Table 4. Prediction model for severe prognosis Based on the results of statistical analysis and univariate logistic regression, four clinical characteristics and 18 laboratory findings differed significantly between the two groups (P<0.01) and were significant in univariate logistic regression (P<0.01), as shown in Table 4. In the further feature selection procedure, these features were used to perform multivariate logistic regression with L1 regularization and feature standardization. With a parameter C=3.999 in the regularization, 17 features were finally selected as shown in Table 4. Eventually, the top six features ranked by regression coefficients were chosen as the most predictive features with which to build a prognostic prediction model for severity for patients with moderate COVID-19. The highest prediction accuracy of 91.38% was reached with the selected six features and a linear kernel SVM with 5-fold cross validation, as shown in Figure 2. The SVM model for prognostic prediction had a sensitivity of 0.90 and a specificity of 0.94, with a mean area under the ROC curve of 0.94, as shown in Figure 3. In the formula for the multivariate prognostic prediction model, the intercept a0 was -0.14, and the feature weights for the six most predictive features are shown in Table 4. Discussion The number of patients infected with COVID-19 is still increasing rapidly worldwide. However, specialized and effective treatment is not yet available. Therefore, the early identification of a moderate case's risk developing into a severe or critical one is of great importance due to the high mortality rate among severe and critical cases 6, 7. Timely intervention and active intensive care can help to minimize the progression of the disease. Therefore, paying attention to prognostic prediction for moderate cases can be important. We enrolled 172 patients hospitalized with laboratory-confirmed COVID-19 and diagnosed with moderate COVID-19 at admission. The patient data were systematically analyzed. As a result, six risk factors were identified as the most predictive ones with which to perform prognostic prediction of severity for patients with moderate COVID-19. Consistent with previous research results, patients in the severe group were significantly older than those in the mild group. Older patients presented more comorbidities and were more likely to develop severe or critical COVID-19 5, 6, 25, 26. The proportion of severe cases in males was 61.7%, which was significantly higher than that in females (38.3%), as reported in a recent study 9. Several studies concerning comorbid disease with COVID-19 suggested that adequate attention should be paid to comorbidity 18, 26, 27. In our study, the most common comorbidity was hypertension (36.6%, 63/172), followed by diabetes (15.7%, 27/172) and cardiovascular disease (9.9%, 17/172). Due to the limited sample size, there were no significant differences in comorbidities between the two groups. For all the moderate cases in this study, chest distress, fatigue, and anorexia were significantly different between the two groups, which was consistent with previous reports 28, 29. In addition, in laboratory findings of the moderate cases at admission, significantly higher levels of WBC, N count, N percentage, AST, LDH, TNI, CK, CK-MB, CysC, ESR, CRP, PCT, IL-6, and IL-10 were found in the severe group compared with the mild group. L count, L percentage, A/G, ALB, and Ca, however, were found to be at lower levels in the severe group. The severity of COVID-19 infection may activate neutrophils to produce an immune response to the virus and cause a cytokine storm. Furthermore, considering that aging is related to decreased immune competence 30, elderly patients who died consequently may be due to a weak immune response 16. There were no significant differences in the L subsets between the two groups, possibly because of the limited sample size. However, some impressive different results were reported in previous research, indicating that CD3+ and CD4+ T cells might protect patients from developing ARDS 16. In this study, a feature selection procedure based on machine learning algorithms was performed to identify the most predictive features for a multivariate prognostic prediction of severity. Feature selection was an essential step for multivariate modeling. In previous studies, this was mainly implemented by performing univariate statistical analysis or with prior clinical knowledge or evidence 9, 15, 17, 19. In our study, a two-step feature selection procedure was performed based completely on patient data. Finally, one clinical characteristic (chest distress) and five laboratory findings (IL-6, TNI, PCT, CRP, Ca) were identified as the most predictive risk factors for prognostic prediction of severity for patients with moderate COVID-19. Without adequate knowledge about COVID-19, information completely extracted from the data may be of great value to perform valid prognostic prediction. The level of IL-6 was mildly elevated or within the normal range in the mild group but markedly elevated in the severe group. Elevated cytokines were likely produced by highly inflammatory macrophages that were implicated in a cytokine storm 31. Myocardial damage with biomarker elevations was a prominent feature in COVID-19 and was related to a worse prognosis 32, 33. TNI, as one of the most predictive factors in our prognostic prediction model, was used to evaluate patients with suspected acute coronary syndrome 34. TNI level in plasma and CRP level were positively and significantly related 35. This implies that the pathological process of myocardial damage and inflammation might have a close relationship in the course of COVID-19 disease. Chest distress was an important factor that could contribute to the prognostic prediction of severity in this study and was reported as one of the most common symptoms in COVID-19 28. Increasing PCT level was reported in the discrimination between mild and moderate cases 36. In our study, PCT was identified as a risk factor for prognostic prediction of severity. Lower level of Ca was recognized as a predictor of severity in our prognostic prediction model. This was an interesting result that has not yet been reported. There are also some limitations in our research. First, a larger sample size may result in a more convincing prognostic prediction model with the feature selection procedure based on machine learning algorithms. Due to the limited size, the comorbidities and some signs and symptoms showed no significant difference between the two groups. Moreover, age was not one of the most predictive factors related to severity in this cohort of moderate cases, but age was an important risk factor in prognosis in previous research 9. Second, the temporal changes in patient characteristics from admission to outcome were not included in this study because most of the tests were performed only once at admission. The prognosis may benefit from information on temporal changes 19. Third, the patients' stage of disease progression at admission, such as time since symptom onset and exposure history, was not considered as a candidate predictor. This information relied on patients' memory and might have been affected by recall bias. Fourth, the data in this study were from an outbreak, so these might differ in a nonoutbreak situation. However, since we included as many COVID-19 cases as possible in our hospital, we believe our study population is representative of cases diagnosed and treated in Wuhan. Conclusions With the data collected at admission, one clinical characteristic (chest distress) and five laboratory findings (IL-6, TNI, PCT, CRP, Ca) showed the best performance in discriminating between the two groups with a linear kernel SVM model. They may be risk factors that can be used to perform a prognostic prediction of severity for patients with moderate COVID-19 in the early stage of the disease and thus help minimize the progression of the disease. We are grateful to the many frontline medical staff for their dedication in the face of this outbreak. Author Contributions Chen Zhao, Yan Bai, Cencen Wang, Yanyan Zhong, Na Lu, Li Tian, Fucheng Cai, and Runming Jin collected the clinical data. Chen Zhao and Yan Bai performed the data analysis and drafted the manuscript. Chen Zhao, Yan Bai and Runming Jin revised the manuscript and approved the final manuscript. Abbreviations COVID-19 Coronavirus Disease 2019 ICU intensive care unit ARDS acute respiratory distress syndrome WHO World Health Organization RT-PCR quantitative real-time reverse transcription polymerase chain reaction COPD chronic obstructive pulmonary disease HIV human immunodeficiency virus SVM support vector machine IQR interquartile range SD standard deviation WBC white blood cell N neutrophil AST aspartate aminotransferase LDH lactate dehydrogenase TNI high-sensitivity cardiac troponin I CK creatine kinase CK-MB creatine kinase-MB CysC cystatin C ESR erythrocyte sedimentation rate CRP high-sensitivity C-reactive protein PCT procalcitonin IL interleukin L lymphocyte A/G albumin to globulin ratio ALB albumin concentration Ca calcium ROC receiver operating characteristic curve Hb hemoglobin PLT platelet count TB total bilirubin ALT alanine aminotransferase GLB globulin ALP alkaline phosphatase BUN blood urea nitrogen CREA creatinine TG triglyceride Na sodium K Potassium TNF Tumor necrosis factor-α NK natural killer cell Ig Immune globulin ROC Receiver operating characteristic AUC area under curve Figure 1 Study population. Figure 2 Classification accuracy of the prognostic prediction model with a linear kernel SVM model and the top k features. The classification accuracy was measured with 5-fold cross validation. The blue dotted vertical line was drawn at the optimal number 6 with the parameter C=3.999 when the classification accuracy reached the highest point 91.38%. The six most predictive features used in the prognostic prediction model were IL-6, TNI, PCT, CRP, chest distress and Ca. Figure 3 The ROC curves for the prognostic prediction model with a linear kernel SVM and 5-fold cross validation. With the six most predictive features, the mean area under the ROC curve was 0.94, with a sensitivity of 0.90 and a specificity of 0.94. Table 1 Comparison of epidemiology and baseline characteristics between mild and severe outcomes of patients with COVID-19 Characteristics Total cases (n=172) Mild (n=112) Severe (n=60) P value Demographics Age (years) 65 (57-71) 64 (50-67) 70.6 (11.6) <0.001a Gender Female 90 (52.3%) 67 (59.8%) 23 (38.3%) 0.01b Male 82 (47.7%) 45 (40.2%) 37 (61.7%) Comorbidities Background Diseases 95 (55.2%) 57 (50.9%) 38 (63.3%) 0.107b Hypertension 63 (36.6%) 38 (33.9%) 25 (41.7%) 0.318b Cardiovascular disease 17 (9.9%) 7 (6.3%) 10 (16.7%) 0.033b Diabetes 27 (15.7%) 12 (10.7%) 15 (25.0%) 0.016b Malignancy 7 (4.1%) 4 (3.6%) 3 (5.0%) 0.694 Cerebrovascular disease 5 (2.9%) 1 (0.9%) 4 (6.7%) 0.049 COPD 4 (2.3%) 2 (1.8%) 2 (3.3%) 0.609 Chronic kidney disease 3 (1.7%) 1 (0.9%) 2 (3.3%) 1.000 Chronic liver disease 3 (1.7%) 2 (1.8%) 1 (1.7%) 1.000 HIV infection 1 (0.6%) 1 (0.9%) 0 (0) 1.000 rheumatic disease 3 (1.7%) 3 (2.7%) 0 (0) 0.552 hyperuricemia 4 (2.3%) 1 (0.9%) 3 (5.0%) 0.119 Note: Categorical data are n (%). Continuous data are the mean (SD) if following a normal distribution according to the Shapiro-Wilk test (P<0.01); otherwise, the median (lower quartile-upper quartile) is shown. a: Mann-Whitney U test; b: chi-squared test; otherwise, Fisher's exact test, owing to an expected count less than five for at least one cell. Table 2 Comparison of signs and symptoms between mild and severe outcomes of patients with COVID-19 Signs and symptoms Total cases (n=172) Mild (n=112) Severe (n=60) P value Fever 109 (63.4%) 71 (63.4%) 38 (63.3%) 1a Dry cough 95 (55.2%) 64 (57.1%) 31 (51.7%) 0.523a Expectoration 30 (17.4%) 19 (17.0%) 11 (18.3%) 0.836a Pharyngalgia 9 (5.2%) 6 (5.3%) 3 (5.0%) 1 Runny nose 7 (4.1%) 4 (3.6%) 3 (5.0%) 0.696 Headache 7 (4.1%) 5 (4.5%) 2 (3.3%) 1 Chest distress 59 (34.3%) 24 (21.4%) 35 (58.3%) <0.001 Pectoralgia 4 (2.3%) 3 (2.7%) 1 (1.7%) 1 Myalgia 38 (22.1%) 24 (21.4%) 14 (23.3%) 0.848a Fatigue 100 (58.1%) 55 (49.1%) 45 (75%) 0.001a Anorexia 75 (43.6%) 37 (33.0%) 38 (63.3%) <0.001a Diarrhea 15 (8.7%) 9 (8.0%) 6 (10%) 0.778a Emesis 7 (4.1%) 5 (4.5%) 2 (3.3%) 1 Ageusia 21 (12.2%) 13 (11.6%) 8 (13.3%) 0.808a Anosmia 32 (18.6%) 19 (17.0%) 13 (21.7%) 0.538a Note: Categorical data are n (%); a: Chi-squared test; otherwise, Fisher's exact test, owing to expected count less than five for at least one cell. Table 3 Comparison of laboratory findings between mild and severe outcomes of patients with COVID-19 Laboratory findings Total cases (n=172) Mild (n=112) Severe (n=60) P value Hematologic parameters WBC (G/L) 5.8 (4.5-7.3) 5.4 (4.4-6.9) 6.5 (5.1-7.9) 0.006 N percentage (%) 64.9 (56.2-73) 60.6 (54.6-66.6) 74.8 (65.5-86.6) <0.001 N (G/L) 3.56 (2.75-5.02) 3.32 (2.52-4.31) 4.69 (3.38-6.51) <0.001 L percentage (%) 22.8 (10.8) 26.8 (8.9) 15.4 (10.1) <0.001a L (G/L) 1.29 (0.86-1.67) 1.51 (1.11-1.77) 0.81 (0.53-1.29) <0.001 Hb (g/L) 120 (15) 121 (12) 119 (19) 0.535a PLT (G/L) 216 (165-280) 224 (180-291) 208 (92) 0.036 Biochemical parameters TB (µmol/L) 11.5 (9.1-14.1) 11.2 (3.5) 12.2 (9.8-18) 0.01 ALT (U/L) 28 (18-49) 27 (18-46) 34 (18-52) 0.429 AST (U/L) 26 (20-37) 23 (20-30) 32 (24-47) 0.001 A/G 1.20 (1.10-1.55) 1.40 (1.20-1.70) 1.10 (0.90-1.28) <0.001 ALB (g/L) 36.0 (32.1-40.3) 38.2 (4.6) 31.1 (28.0-35.0) <0.001 GLB (g/L) 27.8 (24.6-32.2) 28.0 (5.1) 30.3 (6.2) 0.01a ALP (U/L) 77 (63-99) 76 (62-98) 84 (69-106) 0.096 LDH (U/L) 200 (167-273) 181 (164-230) 273 (211-407) <0.001 TNI (ng/L) 2.80 (1.40-8.18) 1.80 (1.00-3.75) 10.1 (3.1-170) <0.001 CK (U/L) 56.5 (39.8-87.3) 51 (39-73) 75 (41-142) 0.003 CK-MB (ng/mL) 0.50 (0.30-1.00) 0.40 (0.30-0.68) 0.95 (0.50-2.80) <0.001 CysC (mg/L) 1.13 (0.95-1.39) 1.08 (0.91-1.23) 1.25 (1.02-1.78) 0.001 BUN (mmol/L) 4.30 (3.50-5.38) 4.20 (3.49-5.00) 4.50 (3.66-9.61) 0.012 CREA (µmol/L) 66 (57-81) 65 (56-75) 75 (58-92) 0.027 TG (mmol/L) 1.38 (1.01-1.86) 1.41 (1.02-1.91) 1.32 (1.00-1.77) 0.389 Na (mmol/L) 139 (137-141) 140 (138-141) 139 (6) 0.161 K (mmol/L) 4.14 (3.72-4.50) 4.15 (0.45) 4.12 (0.86) 0.753a Ca (mmol/L) 2.38 (0.17) 2.30 (0.15) 2.13 (0.16) <0.001a ESR (mm/h) 38 (20-59) 37.4 (22.3) 51.3 (27.1) 0.004a CRP (mg/L) 4.2 (2.9-36.8) 3.1 (1.0-8.1) 76.4 (14.0-132.8) <0.001 PCT (µg/L) 0.13 (0.09-0.13) 0.13 (0.06-0.13) 0.13 (0.13-0.21) <0.001 Cytokine levels IL-6 (pg/ml) 11.1 (5.9-33.1) 8.1 (5.4-11.5) 54.7 (27.5-88.4) <0.001 TNF-α (pg/ml) 3.55 (2.73-5.47) 3.72 (2.79-5.80) 3.28 (2.51-4.90) 0.181 IL-4 (pg/ml) 2.83 (2.08-3.76) 3.14 (2.11-3.85) 2.53 (2.06-3.34) 0.063 IL-2 (pg/ml) 2.97 (2.56-3.97) 3.12 (2.60-4.06) 2.87 (2.56-3.66) 0.242 IL-10 (pg/ml) 4.27 (3.43-5.22) 4.10 (3.09) 4.71 (3.66-6.10) 0.006 IFN-γ (pg/ml) 2.87 (2.13-3.50) 2.97 (2.09-3.51) 2.63 (2.15-3.50) 0.635 Lymphocyte subpopulation CD4+/CD8+ 1.93 (1.49-2.84) 1.86 (1.47-2.68) 2.16 (1.53-3.30) 0.101 CD3+ (%) 75.5 (68.2-80.8) 73.9 (9.4) 75.2 (66.2-81.6) 0.826 CD4+ (%) 45.4 (10.7) 45.2 (9.3) 45.6 (13.1) 0.824a CD8+ (%) 23.7 (17.8-29.3) 24.7 (8.3) 19.8 (15.0-30.3) 0.078 B lymphocyte (%) 11.1 (8.2-15.5) 12.1 (5.2) 10.1 (8.3-16.2) 0.650 NK (%) 7.6 (4.7-12.0) 7.2 (4.9-12.0) 9.5 (3.7-12.0) 0.491 Immuneglobulin IgG (g/L) 10.9 (9.3-12.8) 11.5 (9.8-13.2) 10.2 (8.1-11.6) 0.052 IgA (g/L) 2.43 (1.70-3.04) 2.56 (1.15) 2.56 (1.35) 0.991a IgM (g/L) 1.01 (0.75-1.33) 1.05 (0.80-1.36) 0.86 (0.56-1.10) 0.092 IgE (IU/ml) 33.8 (13.4-102.5) 30.3 (11.3-64.0) 47.9 (16.8-182.7) 0.039 Complement C3 (g/L) 0.87 (0.80-0.98) 0.86 (0.13) 0.92 (0.21) 0.203a C4 (g/L) 0.21 (0.07) 0.20 (0.06) 0.24 (0.10) 0.027 Note: Continuous data are the mean (SD) if following a normal distribution according to the Shapiro-Wilk test (P<0.01); otherwise, median (lower quartile-upper quartile); a: Independent variable t-test; otherwise, Mann-Whitney U test. Table 4 Risk factors associated with the severity of patients with COVID-19 Demographics and clinical characteristics Univariable OR (95% CI) P value Regression coefficient Feature weight Age, years* 1.086 (1.050-1.124) <0.001 0.08 Chest distress 5.133 (2.592-10.168) <0.001 1.05a 0.41 Fatigue 3.109 (1.557-6.210) 0.001 0.55 Anorexia 3.501 (1.816-6.749) <0.001 0.20 Laboratory findings WBC (G/L)* 1.27 (1.08-1.49) 0.003 N percentage (%)* 1.10 (1.07-1.14) <0.001 0.19 N (G/L)* 1.27 (1.09-1.48) 0.002 0.29 L percentage (%)* 0.88 (0.84-0.92) <0.001 0.72 L (G/L)* 0.10 (0.05-0.24) <0.001 0.46 TB (µmol/L)* 1.125 (1.047-1.209) 0.001 TNI (ng/L)* 1.113 (1.048-1.181) <0.001 3.87a 0.74 CysC (mg/L)* 3.079 (1.441-6.579) 0.004 0.33 A/G* 0.031 (0.008-0.114) <0.001 0.43 ALB (g/L)* 0.800 (0.738-0.867) <0.001 0.32 Ca (mmol/L)* 0.001 (0.000-0.012) <0.001 0.82a -0.38 CK (U/L)* 1.007 (1.003-1.012) 0.002 0.45 LDH (U/L)* 1.012 (1.007-1.017) <0.001 ESR (mm/h)* 1.024 (1.007-1.041) 0.005 PCT (µg/L)* 1.2e4 (22-7.4e6) 0.004 1.19a 0.96 CRP (mg/L)* 1.061 (1.038-1.085) <0.001 1.17a 1.13 IL-6 (pg/ml)* 1.115 (1.074-1.157) <0.001 11.97a 2.13 IL-10 (pg/ml)* 1.474 (1.166-1862) 0.001 Note. *Per 1 for unit increase. The regression coefficient indicated the weights of the selected features in the multivariate logistic regression with L1 regularization and feature standardization. The parameter C had a value of 3.999 in this regression with L1 regularization. a: The features that were chosen for a prognostic prediction of severity for patients with moderate COVID-19. The feature weight indicated the weight for each feature used in the probability calculation formula for the prediction of severity in the prognostic model of a linear kernel SVM classifier. ==== Refs 1 Li Q Guan XH Wu P Wang XY Zhou L Tong YQ Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia New England Journal of Medicine 2020 382 1199 207 2 Chinazzi M Davis JT Ajelli M Gioannini C Litvinova M Merler S The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak Science 2020 368 395 400 32144116 3 Wu ZY McGoogan JM Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention Jama-Journal of the American Medical Association 2020 323 1239 42 4 WHO. Coronavirus disease (COVID-19) Situation Report - 119. 2020. WHO; 2020 https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200518-covid-19-sitrep-119.pdf?sfvrsn=4bd9de25_4 5 Guan W Ni Z Hu Y Liang W Ou C He J Clinical Characteristics of Coronavirus Disease 2019 in China New England Journal of Medicine 2020 382 1708 20 6 Huang CL Wang YM Li XW Ren LL Zhao JP Hu Y Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 2020 395 497 506 31986264 7 Yang XB Yu Y Xu JQ Shu HQ Xia JA Liu H Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Lancet Respiratory Medicine 2020 8 475 81 32105632 8 WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). WHO; 2020 https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf 9 Xu PP Tian RH Luo S Zu ZY Fan B Wang XM Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study Theranostics 2020 10 6372 83 32483458 10 Wynants L Van Calster B Bonten MMJ Collins GS Debray TPA De Vos M Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal Bmj-British Medical Journal 2020 369 11 Phua J Weng L Ling L Egi M Lim CM Divatia JV Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations Lancet Respiratory Medicine 2020 8 506 17 32272080 12 Wang Y Lu XF Li YS Chen H Chen TG Su N Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19 American Journal of Respiratory and Critical Care Medicine 2020 201 1430 4 32267160 13 Deng Y Liu W Liu K Fang YY Shang J Zhou L Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study Chinese Medical Journal 2020 133 1261 7 32209890 14 Chen T Wu D Chen HL Yan WM Yang DL Chen G Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Bmj-British Medical Journal 2020 368 15 Zhou F Yu T Du RH Fan GH Liu Y Liu ZB Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Lancet 2020 395 1054 62 32171076 16 Wu CM Chen XY Cai YP Xia JA Zhou X Xu S Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China Jama Internal Medicine 2020 180 934 43 32167524 17 Pan F Yang L Li YC Liang B Li L Ye TH Factors associated with death outcome in patients with severe coronavirus disease-19 (COVID-19): a case-control study International Journal of Medical Sciences 2020 17 1281 92 32547323 18 Li X Xu S Yu M Wang K Tao Y Zhou Y Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Journal of Allergy and Clinical Immunology 2020 19 Li LL Yang L Gui S Pan F Ye TH Liang B Association of clinical and radiographic findings with the outcomes of 93 patients with COVID-19 in Wuhan, China Theranostics 2020 10 6113 21 32483442 20 Du RH Liang LR Yang CQ Wang W Cao TZ Li M Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study European Respiratory Journal 2020 55 21 Chen R Liang W Jiang M Guan W Zhan C Wang T Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China Chest 2020 22 National Health Commission of the People's Republic of China. Notice on the issuance of a new coronavirus pneumonia diagnosis and treatment plan (try the fifth revised version). National Health Commission of the People's Republic of China; 2020 http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml 23 Li LL Fan WL Li J Li QL Wang J Fan Y Abnormal brain structure as a potential biomarker for venous erectile dysfunction: evidence from multimodal MRI and machine learning European Radiology 2018 28 3789 800 29600478 24 Pedregosa F Varoquaux G Gramfort A Michel V Thirion B Grisel O Scikit-learn: Machine Learning in Python Journal of Machine Learning Research 2011 12 2825 30 25 Wang DW Hu B Hu C Zhu FF Liu X Zhang J Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China Jama-Journal of the American Medical Association 2020 323 1061 9 26 Chen NS Zhou M Dong X Qu JM Gong FY Han Y Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Lancet 2020 395 507 13 32007143 27 Wang T Du Z Zhu F Cao Z An Y Gao Y Comorbidities and multi-organ injuries in the treatment of COVID-19 Lancet 2020 395 E52 32171074 28 Mo P Xing Y Xiao Y Deng L Zhao Q Wang H Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2020 29 Han R Huang L Jiang H Dong J Peng H Zhang D Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia American Journal of Roentgenology 2020 215 338 43 32181672 30 Goronzy JJ Fang FQ Cavanagh MM Qi Q Weyand CM Naive T Cell Maintenance and Function in Human Aging Journal of Immunology 2015 194 4073 80 31 Pedersen SF Ho Y-C SARS-CoV-2: a storm is raging Journal of Clinical Investigation 2020 130 2202 5 32 Shi SB Qin M Shen B Cai YL Liu T Yang F Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China JAMA Cardiology 2020 5 802 10 32211816 33 Ruan QR Yang K Wang WX Jiang LY Song JX Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Intensive Care Medicine 2020 46 846 8 32125452 34 Chapman AR Lee KK McAllister DA Cullen L Greenslade JH Parsonage W Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome Jama-Journal of the American Medical Association 2017 318 1913 24 35 Guo T Fan YZ Chen M Wu XY Zhang L He T Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) JAMA Cardiology 2020 5 811 8 32219356 36 Qiu HY Wu JH Hong L Luo YL Song QF Chen D Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study Lancet Infectious Diseases 2020 20 689 96 32220650